Docetaxel - maximising outcomes towards cure in early breast cancer

Breast

Volumn 15, Issue SUPPL. 3, 2006, Pages

  Eiermann, Wolfgang ^a,b  

^a Redcross Women's Hospital   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Adjuvant therapy; Breast cancer; Docetaxel; Efficacy; Safety

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; NAVELBINE; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; EARLY CANCER; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; HIGH RISK PATIENT; HUMAN; INDIVIDUALIZATION; INFECTION; META ANALYSIS; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA AND VOMITING; NEUROTOXICITY; OUTCOMES RESEARCH; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK REDUCTION; SEPSIS; STOMATITIS; SYMPTOMATOLOGY; SYSTEMATIC REVIEW;

EID: 33947227807     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(07)70005-X     Document Type: Article

References (11)

1. Martin M., Pienkowski T., Mackey J., Pawlicki M., Guastalla J., Weaver C., et al. Adjuvant docetaxel plus doxorubicin and cyclophosphamide for node-positive breast cancer. N Engl J Med 352 22 (2005) 2302-2313
2. Roché H., Fumoleau P., Spielmann M., Canon J., Delozier T., Kerbrat P., Serin D., et al. Five years analysis of the PACS 01 trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer. Proc SABCS (2004) Abstract 27.
3. Martin M., Lluch A., Seguí M., Antón A., Fernández-Chacón C., Ruíz A., Ramos M., et al. Toxicity and health-related quality of life (HRQoL) in node-negative breast cancer (BC) patients (pts) receiving adjuvant treatment with TAC (docetaxel, doxorubicin, cyclophosphamide) or FAC (5-fluorouracil, doxorubicin, cyclophosphamide): Impact of adding prophylactic growth factors (GF) to TAC. GEICAM Study 9805. Proc Am Soc Clin Oncol 23 Suppl 16 (2005) 29S Abstract 904.
4. Martin M., Lluch A., Segui M., Ruiz A., Ramos M., Adrover E., et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 17 8 (2006) 1205-1212
5. Lyman G. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Canc Netw 3 4 (2005) 557-571
6. Aapro M., Cameron D., Pettengell R., Bohlius J., Crawford J., Ellis M., Kearney N., et al. European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42 (2006) 2433-2453
7. Smith T., Khatcheressian J., Lyman G., Ozer H., Armitage J., Balducci L., et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24 19 (2006) 3187-3205
8. Martin M., and Vogel C. Adjuvant docetaxel for node-positive breast cancer. Letter. N Engl J Med 353 (2005) 954
9. Jones S., Savin M., Holmes F., O'Shaughnessy J., Blum J., Vukelja S., George T., et al. Final analysis: TC (docetaxel/cyclophosphamide, 4 cycles) has a superior disease-free survival compared to standard AC (doxorubicin/cyclophosphamide) in 1016 women with early stage breast cancer. SABCS (2005) Abstract 40.
10. Joensuu H., Kellokumpu-Lehtinen P., Bono P., Alanko T., Kataja V., Asola R., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354 8 (2006) 809-820
11. Eiermann W., Pienkowski T., Crown J., Chap L., Pawlicki M., Martin M., Chan A., et al. Phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (ACT) in Her-2/neu negative early breast cancer patients with positive axillary lymph nodes: Interim analysis of the BCIRG 005 study. Proc SABCS (2005) Abstract 1069.